Research Article

Crocus sativus L. Tepal Extract Induces Apoptosis in Human U87 Glioblastoma Cells

Shoib Ahmad Baba,1 Maryam Vahedi,2 Irfan Ahmad,3 Bodour S. Rajab,4 Ahmad O. Babalghith5, Safia Irfan,6 and Md. Jamal Hossain7

1Department of Education, Government of Jammu, And Kashmir, India
2Department of Horticultural Science, Faculty of Agricultural Sciences and Engineering, College of Agriculture and Natural Resources, University of Tehran, Karaj, Iran
3Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
4Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
5Medical Genetics Department College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
6Department of Biosciences, Faculty of Science, Integral University, Lucknow, India
7Department of Pharmacy, State University of Bangladesh, 77 Satmasjid Road, Dhanmondi, Dhaka, Bangladesh

Correspondence should be addressed to Shoib Ahmad Baba; shoaibnazir25@gmail.com and Md. Jamal Hossain; jamal.du.p48@gmail.com

Received 22 April 2022; Accepted 21 May 2022; Published 10 June 2022

Academic Editor: Riaz Ullah

Copyright © 2022 Shoib Ahmad Baba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Crocus sativus (C. sativus) is considered as the costliest spice and an important medicinal plant. Herein, we investigated the effects of tepal extract (TE) of C. sativus on the viability of the human glioblastoma cells. Results revealed that TE significantly (P < 0.05) inhibited the proliferation of U87 glioblastoma cells in a dose-dependent manner with comparatively lower toxic effects against normal astrocytes. The IC50 of TE against U87 glioblastoma cells was found to be 130 μg/mL as compared to 600 μg/mL against normal astrocytes. TE also inhibited the colony formation of U87 cells significantly (P < 0.05). The AO/EB and Annexin V/PI staining assays indicated that TE stimulated apoptosis in U87 cells dose dependently. The early and late apoptotic U87 cells increased from 0.66% and 2.3% at control to 14.2% and 21.4% at 260 μg/mL of TE. Moreover, TE caused upregulation of Bax and suppression of Bcl-2. Wound healing assay showed that migration of the U87 cells was suppressed significantly (P < 0.05) at 80 μg/mL of TE. Taken together, these results suggest that TE exhibits antiproliferative effects against U87 glioma cells and may prove to be an important source of natural anticancer agents.

1. Introduction

Crocus sativus L. (C. sativus) belonging to family Iridaceae is an important medicinal plant [1]. Medicinal properties of C. sativus are generally attributed to the presence of a specific group of compounds. These compounds are formed by the oxidative cleavage of carotenoids and are commonly known as apocarotenoids. These apocarotenoids include crocin, safranal, and picrocrocin in considerable quantities [2]. In addition to apocarotenoids, C. sativus is also a rich source of flavonoids such as kaempferol, taxifolin, and naringenin, to name a few [3, 4]. C. sativus has array of medicinal properties, for instance, antidiabetic, anti-inflammatory, cardioprotective, and anticancer [5]. Samarghandian et al. showed that C. sativus extract inhibits pulmonary tumor suppression via activation of apoptosis [6]. Bakshi et al. showed that crocin from C. sativus induces apoptosis and cell cycle arrest of the pancreatic cancer cells [7]. In yet another study, D’Alessandro et al. showed that C. sativus stigma extract stimulates apoptosis to suppress proliferation of the human prostate cancer cells [8]. Nonetheless, there is little information on the antiproliferative effects of tepal extracts of C. sativus. The present study was therefore undertaken to determine the anticancer properties of C. sativus.
tepals extract against the human U87 glioma cells and to unravel the possible underlying molecular mechanisms.

Gliomas are prevalent type of tumors of central nervous system and responsible for significant number of human mortalities [9]. As per the American Brain Tumor Association, gliomas constitute 24.7% of all the primary brain tumors and 74.6% of all malignant tumors [10]. Unfortunately, the survival rate of the glioma patients is very poor. The average survival period of the patients with the currently available treatment strategies is less than 60 months for low-grade glioma and below 15 months for the advanced stage disease [11]. Therefore, there is urgent need to identify efficient treatment strategies for the management and improvement of survival rates of the glioma patients. Consistently, the present study was undertaken to examine the effects of C. sativus tepal extract against the human U87 glioma cells and to determine the survival rates of the glioma patients. Therefore, there is urgent need to identify available treatment strategies for the management and improvement of survival rates of the glioma patients. Consistently, the present study was undertaken to examine the effects of C. sativus tepal extract (TE) against the human glioma cells. This study will form basis for the identification of lead molecules from C. sativus for anticancer chemotherapy.

2. Materials and Methods

2.1. Cell Lines and Culture Conditions. The U87 glioblastoma cells were cultured in DMEM/F12 containing 10% fetal bovine serum in a humidified atmosphere containing 5% CO₂ at 37°C. Astrocyte growth medium from an AGM-Astrocyte Medium Bullet kit (Lonza) was used for the maintenance of normal human astrocytes.

2.2. Preparation of the C. sativus Tepal Extract. The extract was prepared from shade dried tepals (100 g) of C. sativus by maceration with ethanol as described previously [12]. The tepal extract (TE) was then filtered and concentrated at 50°C under reduced pressure on a Rotavapor®. The resultant extract was used for further experiments.

2.3. Cell Viability Assay. The glioma U87 and the normal astrocytes were added in 96-well plates with of 5×10³ cells/well. Then, treatment of the cells with different concentrations (0 to 640 μg/L) of TE for 24 h at 37°C was followed. Next, 10 μL of MTT (5 mg/mL) was followed by an additional 4 h incubation at 37°C. Thereafter, DMSO (10%) was used to solubilize the formazan crystals. Finally, OD₅₇₀ was determined by using spectrophotometer to estimate cell viability.

2.4. Colony Formation Assay. Around 5000 U87 glioma cells were seeded in 12-well plates and treated with varied concentrations of TE. The plates were incubated for 14 days at 37°C, and the colonies so developed were fixed in paraformaldehyde for 20 minutes, PBS washed, and subjected to staining for with 0.1% crystal violet for 35 minutes. The visible colonies were PBS washed and photographed under a microscope. The colonies were finally counted using the Image J software.

2.5. Acridine Orange and Ethidium Bromide (AO/EB) Staining. AO/EB staining was carried out for the detection of apoptosis in U87 glioma cells. Briefly, the U87 cells were seeded in coverslips with 5×10⁵/wells and cultured for 24 h at 37°C. Then, the culture medium was replaced with a fresh medium containing different concentrations of TE. The cells were then again incubated at 37°C for 24 h. Subsequently, AO/EB staining of monolayer cells was performed. Finally, the cells were examined under a fluorescence microscope (×200) magnification, and images were captured.

2.6. Annexin V/PI Assay. The U87 glioma cells were collected and then suspended in 500 μL of 1X binding buffer. Then, Annexin V-FITC (5 μL) was added to the suspension followed by PI (10 μL) (Annexin V-FITC detection Kit, Beyotime Biotechnology). The cells were mixed evenly and refrigerated at 4°C for 10 min in the dark. Flow cytometer (Accuri C6, Becton-Dickinson, US) was used to detect the apoptotic cells.

2.7. Wound Healing Assay. U87 cells were cultured in 6-well plates with density of 1×10⁵ cells/wells to confluent monolayers and subsequently subjected to overnight starvation in serum-free media. Wound scratching was done by sterile pipette tips. The plates were washed to remove the debris, treated with TE, and subjected to incubation for 24 h at 37°C. The wound gaps were photographed at 0 and 24 h time intervals to determine cell migration.

2.8. Western Blotting Assay. Treated and control U87 cells were subjected to washing with PBS lysed in ice cold lysis buffer. The protein concentration of each sample was determined by Bio-Rad protein assay kit. Whole-cell lysates (30 μg) were separated by 12% polyacrylamide gel electrophoresis and subsequently moved to a polyvinylidene difluoride membrane. Afterwards, western blot analysis was used for specific primary antibodies Bax (sc-7480, Santa Cruz, CA, USA), Bcl-2 (sc-23960, Santa Cruz, CA, USA), and Actin (sc-58673, Santa-Cruz, CA, USA). The membranes were washed three times with TBST and incubated for 2 h with appropriate HRP-conjugated secondary antibody anti-rabbit IgG HRP (Cell Signaling Technology, 7074s, 1:2000). Signals were visualized by using the Enhanced Chemiluminescence Plus (ECL Plus) detection system (GE Healthcare).

2.9. Statistical Analysis. Each experiment was done with three replicates, and data was shown as mean ± SD. Statistical analysis was carried out by using t-test through GraphPad prism 7, and P < 0.05 indicated statistically significant difference.

3. Results

3.1. TE Inhibits the Proliferation of Glioblastoma Cells. The effects of TE were evaluated against the U87 glioma and normal human astrocytes by MTT cell viability assay (Figure 1). It was revealed that the viability of U87 cells diminished significantly (P < 0.05) in a dose-dependent manner. At 320 μg/mL of the extract, the cell viability was inhibited by 96.5%. However, the antiproliferative effects of TE were milder against the normal astrocytes. The IC₅₀ of TE was found to be 130 μg/mL against the U87 cells as compared to an IC₅₀ of 600 μg/mL against the normal astrocytes suggestive of cancer specific antiproliferative effects of TE. Next, the
effects of TE were assessed on the colony-forming potential of U87 cells. Results indicated that the colony formation ability of the U87 cells decreased significantly \((P < 0.05)\). Compared to control, the colony formation potential of the U87 cells decreased by 85% at 320 \(\mu\)g/mL of TE. These findings clearly suggest the antiproliferative effects of TE against U87 glioblastoma cells.

3.2. TE Induces Apoptosis in Glioblastoma Cells. To find out how TE inhibits the proliferation of the U87 cells, AO/EB staining was performed. AO/EB staining revealed apoptosis to be responsible for the inhibition of proliferation by TE. Fluorescence microscopy showed the presence of different types of cells. The bright green color cells indicate the normal viable cells, the yellowish cells represent early apoptotic, orange cells represent late apoptotic, and the red color cells represent the necrotic cells (Figure 2(a)). Next, Annexin V/PI assay was performed to find out the percentage of apoptotic U87 glioblastoma cells at each concentration of TE. The early and late apoptotic U87 cells increased from 0.66% and 2.3% at control to 14.2% and 21.4% at 260 \(\mu\)g/mL of TE respectively (Figure 2(b)). Western blotting revealed that the expression of Bax increased and that of Bcl-2 decreased upon treatment of the U87 cells with TE (Figure 2(c)). These findings indicate that TE stimulates apoptosis in U87 glioblastoma cells.

3.3. \textit{C. sativus} Extract Suppresses the Migration of Glioblastoma Cells. Next, the effects of TE were also assessed on the migration of the U87 glioblastoma cells by wound healing assay. To overrule the antiproliferative effects, lower dosage of TE (80 \(\mu\)g/mL) was used in wound healing assay. The results showed that TE extract significantly \((P < 0.05)\) inhibited the migration of the U87 cells (Figure 3).
Control 65 µg/mL

130 µg/mL 260 µg/mL

(a)

10^5

10^4

10^3

10^2

10^1

10^0

0

Annexin-V FITC

PI

(b)

Figure 2: Continued.
4. Discussion

Plants have served and will continue to serve as an important repository of bioactive compounds [13, 14]. The compounds or their derivatives have been used as drugs or lead molecules for the development of drugs to treat human ailments [15–17]. Several well-known drugs currently used for the treatment of deadly disease have their origin in plants [18]. C. sativus is a well-known medicinal plant, and a wide array of pharmacological properties have been attributed to different parts of this plant [5]. Nonetheless, effects of TE have not been evaluated against human glioblastoma cells. Consistently, herein, we report the anticancer effects of TE against the human glioblastoma cells. It was found that TE inhibited the viability of U87 cells more profoundly as compared to the normal astrocytes. This selective inhibition of U87 cells by TE could be attributed to the fact that several signalling pathways show dysregulation in cancer cells [19], and TE extract might modulate any of these pathways. However, more studies are needed to infer the exact mechanism for the selective inhibition of the U87 cells. Our findings are supported by previous finding wherein C. sativus extracts have been found to suppress the growth of different cancers such as colorectal cancer [20]. Chryssanthi et al. reported that the extracts of different Crocus species exhibit the potential to inhibit the growth of the breast cancer cells [21]. Similarly, Bathaie et al. reported that crocin from C. sativus could inhibit the growth of the human adenocarcinoma gastric cancer growth in vivo [22]. In yet another study, Mir et al. showed that crocetin beta-d-glucosyl ester from C. sativus could inhibit the growth of the human adenocarcinoma gastric cancer growth [23]. Apoptosis is an essential process which eliminates the defective cancerous cells from the body of an organism and helps to maintain homeostasis [24]. In the present study, we found that TE inhibited the proliferation of the U87 cells by inducing apoptosis. However, at IC50 of TE, the percentage of both early and late apoptotic cells was 23.78% indicating that apoptosis alone could not be responsible for the antiproliferative effects of TE. Therefore, more research endeavours are needed to identify other molecular routes through which TE exerts its effects. Nonetheless, our results are supported by a previous study wherein Samarghandian et al. showed that C. sativus extract induces apoptosis in pulmonary tumor [6]. Next, TE also suppressed the migration of the glioblastoma cells indicating that TE may also exhibit antimetastatic potential given that migration is an initial step in the metastasis of cancer [25]. Although the present study revealed the
anticancer potential of TE extract, more studies including in vivo studies are needed. Additionally, the active phytochemical constituents of TE extract need to be identified by natural product chemistry approaches.

5. Conclusion

Collectively, the results of this study revealed that C. sativus tepal extract suppresses the proliferation of human glioblastoma cells via stimulation of apoptosis. Additionally, it could also suppress migration of the glioblastoma cells. These findings suggest that C. sativus tepal extract may prove to be an important source of anticancer agents or anticancer lead molecules. However, further research endeavours involving identification, isolation, and mechanism of action of each component of tepal extract are urgently needed.

Data Availability

All data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors are grateful to Scientific Research Deanship at King Khalid University, Abha, Saudi Arabia for their financial support through the Large Research Group Project under grant number RGP.02-87-43.

References

[1] R. Srivastava, H. Ahmed, and R. K. Dixit, “Crocus sativus L.: a comprehensive review,” Pharmacognosy Reviews, vol. 4, no. 8, p. 200, 2010.
[2] M. Lage and C. L. Cantrell, “Quantification of saffron (Crocus sativus L.) metabolites crocins, picrocrocin and safranal for quality determination of the spice grown under different environmental Moroccan conditions,” Scientia Horticulturae, vol. 121, no. 3, pp. 366–373, 2009.
[3] S. A. Baba, A. H. Malik, Z. A. Wani et al., “Phytochemical analysis and antioxidant activity of different tissue types of Crocus sativus and oxidative stress alleviating potential of saffron extract in plants, bacteria, and yeast,” South African Journal of Botany, vol. 99, pp. 80–87, 2015.
[4] S. A. Baba, R. A. Vishwakarma, and N. Ashraf, “Functional characterization of CsBGlu12, a β-glucosidase from Crocus sativus, provides insights into its role in abiotic stress through accumulation of antioxidant flavonols,” Journal of Biological Chemistry, vol. 292, no. 11, pp. 4700–4713, 2017.
[5] F. Abdullaev, “Biological properties and medicinal use of saffron (Crocus sativus L.),” InII International Symposium on Saffron Biology and Technology, vol. 739, pp. 339–345, 2006.
[6] S. Samarghandian, J. T. Afshari, and S. Davoodi, “Suppression of pulmonary tumor promotion and induction of apoptosis by Crocus sativus L. extraction,” Applied Biochemistry and Biotechnology, vol. 164, no. 2, pp. 238–247, 2011.
[7] H. A. Bakshi, M. S. Al Zoubi, H. L. Faruck et al., “Dietary crocin is protective in pancreatic cancer while reducing radiation-induced hepatic oxidative damage,” Nutrients, vol. 12, no. 6, p. 1901, 2020.
[8] A. M. D’Alessandro, A. Mancini, A. R. Lizzì et al., “Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer,” Nutrition And Cancer, vol. 65, no. 6, pp. 930–942, 2013.
[9] A. M. Molinaro, J. W. Taylor, J. K. Wiencke, and M. R. Wrensch, “Genetic and molecular epidemiology of adult diffuse glioma,” Nature Reviews Neurology, vol. 15, no. 7, pp. 405–417, 2019.
[10] T. K. Souza, M. P. Nucci, J. B. Mamani et al., “Image and motor behavior for monitoring tumor growth in C6 glioma model,” PLoS One, vol. 13, no. 7, article e0201453, 2018.
[11] B. Delgado-Martín and M. Á. Medina, “Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment,” Advanced Science, vol. 7, no. 9, p. 1902971, 2020.
[12] S. A. Baba, D. Jain, N. Abbas, and N. Ashraf, “Overexpression of Crocus carotenoid cleavage dioxygenase, CsCCD4b, in Arabidopsis imparts tolerance to dehydration, salt and oxidative stresses by modulating ROS machinery,” Journal of Plant Physiology, vol. 189, pp. 114–125, 2015.
[13] F. E. Amrati, M. Bourhia, M. Slighoua et al., “Traditional medicinal knowledge of plants used for cancer treatment by communities of mountainous areas of Fez-Meknes-Morocco,” Saudi Pharmaceutical Journal, vol. 29, no. 10, pp. 1185–1204, 2021.
[14] G. H. Du, Natural Small Molecule Drugs from Plants, Springer, 2018.
[15] M. A. Ashraf, “Phytochemicals as potential anticancer drugs: time to ponder nature’s bounty,” Biomed Research International, vol. 2020, 7 pages, 2020.
[16] M. Bourhia, F. E. Laasri, S. I. Moussa et al., “Phytochemistry, antioxidant activity, antiproliferative effects, and acute toxicity testing of two Moroccan aristolochia species,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, 8 pages, 2019.
[17] M. F. Khan, A. S. Alqahtani, O. M. Almarfadi et al., “The reproductive toxicity associated with Dodonaea viscosa, a folk medicinal plant in Saudi Arabia,” Evidence-Based Complementary and Alternative Medicine, vol. 2021, 9 pages, 2021.
[18] O. S. Borsuk, N. V. Masnaya, E. Y. Sherstoboev, N. V. Isaykina, G. I. Kalinkina, and D. V. Reihart, “Effects of drugs of plant origin on the development of the immune response,” Bulletin of Experimental Biology & Medicine, vol. 151, no. 2, pp. 194–196, 2011.
[19] S. Nisar, S. Hashem, M. A. Macha et al., “Exploring dysregulated signaling pathways in cancer,” Current Pharmaceutical Design, vol. 26, no. 4, pp. 429–445, 2020.
[20] H. H. Aung, C. Z. Wang, M. Ni et al., “Crocin from Crocus sativus possesses significant anti-proliferation effects on human colorectal cancer cells,” Experimental Oncology, vol. 29, no. 3, pp. 175–180, 2007.
[21] D. G. Chryssanthi, F. N. Lamari, G. Iatrou, A. Pyla, N. K. Karamanos, and P. Cordopatis, “Inhibition of breast cancer cell proliferation by style constituents of different Crocus species,” Anticancer Research, vol. 27, no. 1, pp. 357–362, 2007.
[22] S. Z. Bathaie, R. Hoshyar, H. Miri, and M. Sadeghizadeh, “Anticancer effects of crocetin in both human adenocarcinoma gastric cancer cells and rat model of gastric cancer,” *Biochemistry and Cell Biology*, vol. 91, no. 6, pp. 397–403, 2013.

[23] M. A. Mir, S. A. Ganai, S. Mansoor et al., “Isolation, purification and characterization of naturally derived Crocetin beta-d-glucosyl ester from Crocus sativus L. against breast cancer and its binding chemistry with ER-alpha/HDAC2,” *Saudi Journal of Biological Sciences*, vol. 27, no. 3, pp. 975–984, 2020.

[24] S. W. Lowe and A. W. Lin, “Apoptosis in cancer,” *Carcinogenesis*, vol. 21, no. 3, pp. 485–495, 2000.

[25] G. P. Gupta and J. Massagué, “Cancer metastasis: building a framework,” *Cell*, vol. 127, no. 4, pp. 679–695, 2006.